Skip to main content
. 2012 Jul 19;7(7):e41325. doi: 10.1371/journal.pone.0041325

Figure 3. Risk ratio of arterial thromboembolic events associated with intravitreal anti-VEGF treatment compared with control treatment.

Figure 3